1. Introduction {#sec1}
===============

Osteonecrosis of the femoral head (ONFH) is a major worldwide public health concern. Annually, there are 10,000 to 20,000 new cases reported in the United States \[[@B1]\] and 100,000 to 200,000 new cases reported in China \[[@B2]\]. The annual incidence of ONFH as an indication for total hip replacement (THR) has been reported as relatively low in the United States (10%) \[[@B3]\] and the United Kingdom (2%) \[[@B4]\]. Conversely, ONFH has been reported as a major indication for THR in Asian populations: 50% in Korea \[[@B5]\], 49% in India \[[@B6]\], 45% in Taiwan \[[@B7]\], 42% in Singapore \[[@B8]\], and 41.2% in Hong Kong \[[@B9]\].

ONFH is defined as bone cell death due to interruption of the blood supply to the femoral head \[[@B10]\]. Typical ONFH occurs after physical trauma \[[@B11]\], whereas the etiology of nontraumatic ONFH (NONFH) is complex and multifactorial \[[@B12]\]. Steroid usage, alcohol consumption, autoimmune disease (e.g., systemic lupus erythematosus, vasculitis, and rheumatoid arthritis), diabetes, hyperlipidemia, renal failure, dialysis, pancreatitis, and hematologic diseases are all associated with increased risk of NONFH \[[@B12]--[@B16]\]. In Taiwan, alcohol consumption is the most prevalent etiology (45.2%), followed by idiopathic causes (33.1%) and steroid usage (21.7%) \[[@B17]\].

Treatment of ONFH is stage-dependent \[[@B11]\]. Notably, many nonsurgical management strategies, such as Western pharmacological management strategies (lipid-lowering agents, anticoagulants, vasoactive substances, and bisphosphonates) and biophysical treatments (extracorporeal shockwave therapy \[ESWT\], pulse electromagnetic therapy \[PET\], and hyperbaric oxygen therapy \[HBO\]) have been found to improve pain and functional outcomes in the early stage \[[@B18]\]. However, most Western conservative therapies to prevent the onset of THR and delay its progression are controversial and lack sufficient evidence for widespread use \[[@B11], [@B18]\]. Surgical treatment, such as core or multiple drilling decompression in the early stage of NONFH, may be effective in relieving symptoms; however, this approach has no greater value than conservative management in preventing collapse of the femoral head \[[@B12], [@B19], [@B20]\].

Traditional Chinese medicine (TCM) has been widely applied in Asia and reportedly provides pain relief and improved quality of life in NONFH patients \[[@B21], [@B22]\]. However, no evidence has yet indicated that TCM could be useful in the prevention of THR. Therefore, the aim of this nationwide population-based retrospective cohort study was to investigate the association between use of TCM therapy and risk of THR in patients with NONFH.

2. Materials and Methods {#sec2}
========================

2.1. Data Sources {#sec2.1}
-----------------

In Taiwan, TCM has been covered under the government-run National Health Insurance (NHI) program since 1995. This program ensures \> 99% of citizens and is accepted by \> 93% of healthcare institutes \[[@B23]\]. The NHI research database (NHIRD) provides ambulatory care, inpatient care, and management and medication data and is an ideal platform for use in pharmacoepidemiologic studies. Notably, it comprises a random sample that is representative of the general population; moreover, it includes registration files and original claims data for reimbursements, thereby avoiding selection bias and providing researchers with a comprehensive understanding of healthcare utilization, including Western medicine and TCM treatments \[[@B24], [@B25]\]. All diseases in the NHIRD are classified in accordance with the International Classification of Diseases, Ninth Revision, and Clinical Modification (ICD-9-CM). For this study, we used the Longitudinal Health Insurance Database 2000 (LHID2000), which comprises all original claims data for 1 million individuals randomly selected from among all beneficiaries of the NHID.

2.2. Study Population {#sec2.2}
---------------------

From January 1, 2000, to December 31, 2010, a total of 3,146 patients were newly diagnosed with ONFH (ICD-9-CM: 733.42) and underwent radiography or MRI within 1 year ([Figure 1](#fig1){ref-type="fig"}). We excluded patients who (1) underwent THR before the initial diagnosis of ONFH or within 6 months after the date of initial diagnosis (n=949), (2) had records in which data were missing regarding age or sex, or who were less than 18 years of age (n=57), and/or (3) were diagnosed with hip fracture or hip dislocation (ICD-9-CM: 733.14-15, 820.xx, 821.xx, 905.3, 718.25, 718.28-9, 718.3x, and 754.3x, 835.xx) before the endpoint (n=460). Of the remaining 1,680 patients with NONFH, those with at least one medical record in the TCM outpatient clinic were defined as TCM users (n=1,028) and those with no TCM outpatient records were defined as non-TCM users (n=652). For each TCM user, a control subject who was a non-TCM user was randomly selected by propensity score matching, according to age, sex, socioeconomic status, comorbidities, Western drugs used, surgical treatments, and the duration between the diagnosis date and the index date. Diagnosis date was the initial date of NONFH diagnosis. Index date was the first date of TCM use in the TCM group, whereas it was a randomly assigned date between the diagnosis date and the endpoint (see "Primary Outcome" subsection for details) in the non-TCM group ([Figure 2](#fig2){ref-type="fig"}). Finally, 595 propensity-matched pairs of TCM and non-TCM patients were used in this analysis.

2.3. Primary Outcome {#sec2.3}
--------------------

The primary outcome was THR during the study period (2000 to 2013). The endpoint was the date of THR, study withdrawal, or death, whichever occurred first ([Figure 2](#fig2){ref-type="fig"}).

2.4. Covariate Assessment {#sec2.4}
-------------------------

Sociodemographic factors assessed in this study included age, sex, and socioeconomic status. Age was divided into three groups: 18--29 years, 30--59 years, and ≥60 years. Sex was categorized as male or female. Socioeconomic status was divided into two groups according to monthly salary: fixed premium and dependent (\<20,000 New Taiwan Dollar, NTD; 1 USD = 30 NTD) and ensured salary grading above fixed premium (≥20,000 NTD). Baseline comorbidities were considered present if the following ICD-9-CM codes appeared in at least three outpatient claims or one inpatient claim before the initial date of ONFH diagnosis: alcohol-related disease (ICD-9-CM: 291, 303, 303.0, 303.00-03, 303.9, 303.90-93, 305.0, 305.01-03, 357.5, 425.5, 535.3, 535.30-31, 571.0-3, 790.3, 977.3, 980.0, and 980.8-9); autoimmune disease: lupus erythematosus (ICD-9-CM: 695.4, 373.34, 710.0), vasculitis (ICD-9-CM: 136.1, 443.1, 446.0-2, 446.4-5, and 446.7), and rheumatoid arthritis (ICD-9-CM: 714.0); diabetes (ICD-9-CM: 250), hyperlipidemia (ICD-9-CM: 272.0-5, 272.7-9); pancreatitis (ICD-9-CM: 577.0-1); hematologic disease (ICD-9-CM: 205, 238.4, 282, 284, and 286); and renal failure or dialysis (ICD-9-CM: 584-586, 403.01, 403.11, 403.91, 404.02, 404.12, and 404.92; treatment code: 58001C, 58027C, 58029C, and 58002C). Western medicines (e.g., bisphosphonate, anticoagulants, iloprost, statins, oral steroids, or intravenous steroids) and surgical treatments (e.g., cord decompression, bone graft, and osteotomy) between initial diagnosis date and endpoint were also considered.

2.5. Statistical Analyses {#sec2.5}
-------------------------

Differences between the two groups were assessed using the chi-squared test or Fisher\'s exact test for categorical variables and by Student\'s t-test for continuous variables. The Cox proportional hazard model with hazard ratios (HR) and 95% confidence intervals (CI) was used to estimate the association between TCM use and the risk of THR, as well as the risks between TCM use and each of multiple covariates among NONFH patients. Kaplan-Meier analysis and log rank tests were performed to plot the cumulative incidence of THR. A *p* value \<0.05 was considered to be statistically significant. All analyses were performed using SAS statistical software (version 9.4 for Windows; SAS Institute, Inc., Cary, NC, USA).

2.6. Ethical Consideration {#sec2.6}
--------------------------

All patient information that could be used to identify individuals or care providers was deidentified and encrypted before release. The study was approved by the research ethics committee of China Medical University and Hospital (CMUH104-REC2--115(CR-2)).

3. Results {#sec3}
==========

There were no statistically significant differences in age, sex, socioeconomic status, most comorbidities (except autoimmune disease), Western drug use, and surgical treatments between the non-TCM and TCM groups ([Table 1](#tab1){ref-type="table"}). Most patients were male in both groups (73.28% vs 73.78%). The 30--59-year-old group comprised the largest proportion in both groups (65.55% vs. 64.87%). Nearly 60% of patients had income \<20,000 NTD per month (fixed premium and dependent group). Alcohol-related disease was the most common comorbidity, followed by hyperlipidemia and diabetes. Before the endpoint, 90.42% of non-TCM users and 90.76% of TCM users had used oral or intravenous steroids. The mean (median) follow-up periods (from index date to endpoint) were 5.00 (4.38) years and 3.57 (3.35) years for the TCM and non-TCM cohorts.

In the TCM cohort, fewer patients underwent THR surgery, compared to the non-TCM cohort (18.2% vs 25.4%); moreover, the TCM cohort had a lower adjusted hazard ratio (0.60, 95% CI: 0.46-0.77,*p*\< 0.0001), after adjusting for age, sex, socioeconomic status, comorbidities, Western drug use, and surgical treatments ([Table 2](#tab2){ref-type="table"}). Males had a lower risk of THR than females. However, age and socioeconomic status did not affect the risk of THR.

The TCM cohort, compared to the non-TCM cohort, had a significantly lower incidence rate of THR for women and men ([Table 3](#tab3){ref-type="table"}). The TCM cohort also had a significantly lower incidence rate in the 30--59-year-old subgroup. Although there were more THR events in the ≥60-year-old subgroup in the TCM group, the adjusted hazard ratio was equal to 1 (95% CI: 0.58-1.72). However, the TCM cohort had fewer patients undergoing THR surgery regardless of socioeconomic status.

Furthermore, Kaplan-Meier analysis with a log rank test showed a significantly lower cumulative incidence of THR in the TCM cohort (*p*\<0.0001) than in the non-TCM cohort; the cumulative incidence rate in the TCM cohort remained lower for a follow-up period of up to 12 years ([Figure 3](#fig3){ref-type="fig"}).

[Table 4](#tab4){ref-type="table"} shows the 10 most frequently prescribed formulae and single herbs for treating NONFH in Taiwan. Among multiherb products, Shu-Jing-Huo-Xue-Tang (4,106 person-days) was the most commonly prescribed formula. The herb Yan Hu Suo (4,348 person-days), produced by extraction of a single substance, was the most frequently prescribed single herb.

4. Discussion {#sec4}
=============

This study is the first population-based retrospective cohort study regarding the association between TCM use and risk of THR in NONFH patients in Taiwan. Our principal findings were as follows: TCM users had a 0.60-fold lower risk of THR. The risk of reduction was noted in the group aged 30--59 years but was not associated with gender nor socioeconomic status. Furthermore, there was a significantly lower cumulative incidence of THR in TCM users.

TCM has been shown to raise Harris functional scores and improve the quality of life among NONFH patients \[[@B21], [@B22]\]. However, there has been no large-scale study regarding the potential of TCM to lower the risk of requiring joint replacement surgery. In our study, we enrolled 1,120 NONFH patients, evenly divided into TCM users and nonusers; these patients were matched on the basis of age, sex, socioeconomic status, drugs (including steroids) used, and other treatments that may affect the progression of the disease \[[@B12], [@B17]\]. We found that male sex and alcohol consumption were prevalent among NONFH patients ([Table 1](#tab1){ref-type="table"}). These results are similar to findings from other studies in Taiwan \[[@B17]\]. The 30--59-year-old age group included 65% of the patients, which was consistent with a previous finding that NONFH occurs most often between the ages of 30 and 50 \[[@B27]\]. We found that nearly 60% of patients with NONFH were fixed premium and dependent group. Because a previous study showed that low-income patients were less likely than their high-income counterparts to undergo total THR \[[@B26]\], we matched the patients on the basis of socioeconomic status ([Table 1](#tab1){ref-type="table"}) and adjusted the analyses based on income ([Table 2](#tab2){ref-type="table"}). These adjusted results show that TCM users had a significantly lower risk of THR, regardless of socioeconomic status ([Table 3](#tab3){ref-type="table"}). Furthermore, TCM users in all age groups had lower incidence rates of THR. However, only in the 30--59-year-old group (65% of patients) had significantly lower risk. The result may be due to the small sample size among patients aged 18--29 and aged ≥60.

NONFH appears to be related to hypercoagulable states, suppression of angiogenesis, hyperadipogenesis, genetic factors, and transition from bone remodeling to bone resorption \[[@B16]\]. Various immune mechanisms and activation of proinflammatory pathways have also been associated with NONFH \[[@B12]\]. The mechanism by which TCM affects NONFH is unclear and may vary on the basis of herbs or formulae used. TCM herb extractions or formulae can reportedly counteract endothelial injury, excessive adipogenesis, blood stasis, and apoptosis; moreover, they can improve osteogenesis, angiogenesis, and blood circulation, both*in vitro* and*in vivo* \[[@B28]--[@B30]\]. In the present study, the 10 most commonly prescribed formulae and single herbs were as follows. Shu-Jing-Huo-Xue-Tang (SJHXT) was the most commonly prescribed formulae; this has been shown to relieve muscle pain \[[@B31]\], increase blood circulation \[[@B32]\], and enhance antioxidant enzymatic activity \[[@B33]\]. SJHXT also exhibits anti-inflammatory and analgesic activity \[[@B34], [@B35]\]. Jia-Wei-Xiao-Yao-San (JWXYS) and Long-Dan-Xie-Gan-Tang (LDXGT) mediate anti-inflammatory activity through inhibition of cytokines and proinflammatory enzymes \[[@B36], [@B37]\]. However, they have not been shown to improve NONFH. Shao-Yao-Gan-Cao-Tang (SYGCT) has been reported to relieve muscle spasm \[[@B38]\] and spasmodic pain in the musculoskeletal system, including joints, back, and soft tissues \[[@B39], [@B40]\]. SJHXT and SYGCT can enhance kinase signal pathways, which are important in osteoblast differentiation \[[@B41], [@B42]\]. Du-Huo-Ji-Sheng-Tang (DHJST) can regulate the expression of vascular endothelial growth factor and hypoxia-inducible factor, inhibit chondrocyte apoptosis \[[@B43]\], promote osteogenic differentiation, and decrease the aging process of human mesenchymal stem cells \[[@B44]\]. These characteristics may be related to the improvement of NONFH. Ge-Gen-Tang (GGT) is named for its major herb composition, Ge-Gen, which was also a commonly prescribed single herb in our cohort study. The major active compound of Ge-Gen, puerarin, reportedly inhibits adipogenic differentiation and prevents alcohol-induced osteonecrosis \[[@B29]\]. Xue-Fu-Zhu-Yu-Tang (XFZYT) is used to enhance blood circulation, counteract blood stasis, and inhibit inflammatory responses and apoptosis \[[@B45], [@B46]\].

Among single herbs, Yan Hu Suo (YHS) was prescribed most frequently. Tetrahydroprotoberberines, dehydrocorybulbine, and L-tetrahydropalmatine are active components that can be isolated from YHS; these have been demonstrated to exert analgesic and antinociceptive effects on chronic inflammatory and injury-induced neuropathic pain \[[@B47]--[@B50]\]. Niu Xi (NX) has been reported to induce angiogenesis and is used as treatment for bone injury \[[@B51]\]; it is a key component in both SJHXT and XFZYT and was commonly used as treatment for NONFH in our study. Moreover, NX is a key component of the Huogu II formula, which showed preventive and therapeutic effects in an experimental model of ONFH \[[@B52]\]. Dan Shen (DS) has lipid-lowering \[[@B53]\] and anti-inflammatory \[[@B54]\] effects; furthermore, it could protect endothelial cells from hydrogen peroxide damage and inhibit apoptosis \[[@B55]\]. Gan Cao (GC) is very popular in TCM and commonly used in herbal formulae to "harmonize" other ingredients; it has anti-inflammatory, antioxidative, and immunomodulatory effects \[[@B56], [@B57]\].

Each Chinese herb or formula might have different osteogenic, angiogenic, anti-inflammatory, antioxidant, antiadipogenic, and analgesic effects, which contribute to the effect of TCM treatment in reducing the risk of THR among NONFH patients. Overall, TCM treatment might be protective for patients with NONFH.

5. Limitations {#sec5}
==============

This study had some limitations. First, we did not evaluate the amount and frequency of steroid or alcohol usage. Second, Western treatments, such as ESWT, PET, HBO, tantalum implants, and biological agents that lack sufficient evidence, were not covered by the NHI program; thus, these were not evaluated. Herbal decoction and folk medicine are also not covered by the NHI program. Therefore, the utilization of TCM may be underestimated. Third, NONFH severity and stage were not assessed. However, we excluded patients who underwent THR before the initial diagnosis date, as well as those who underwent THR within 6 months after the initial diagnosis date. Finally, we did not assess any adverse drug reactions or interactions between Chinese medicine and Western medicine, although these have been previously reported. Despite these limitations, our findings are representative of the general population because we used population-based data from a national database.

6. Conclusions {#sec6}
==============

In this retrospective population-based cohort study, TCM users had a lower risk of THR. The risk of reduction was noted in the group aged 30--59 years but was not associated with gender nor socioeconomic status. We also found a significantly lower cumulative incidence of THR among TCM users. However, further prospective studies examining the mechanisms of TCM are needed to confirm our findings.
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###### 

Characteristics of NONFH patients according to use of TCM.

  Variables                                                                TCM             *p*-value*∗*                         
  ------------------------------------------------------------------------ --------------- --------------- ------------ ------- -----------
  *Sex*                                                                                                                         0.8437
   Female                                                                  159             26.72           156          26.22    
   Male                                                                    436             73.28           439          73.78    
  *Age group*                                                                                                                   0.8857
   18--29                                                                  34              5.71            38           6.39     
   30--59                                                                  390             65.55           386          64.87    
   ≥60                                                                     171             28.74           171          28.74    
   Mean ± SD                                                               51.71 (15.13)   51.61 (14.58)   0.9124 ^a^           
  *Socioeconomic status*                                                                                                        0.5815
   Fixed premium and dependent                                             359             60.34           348          58.49    
   Insured salary grading above fixed premium                              236             39.66           247          41.51    
  *Comorbidity*                                                                                                                  
   Alcohol-related disease                                                 387             65.04           384          64.54   0.8555
   Autoimmune disease                                                      16              2.69            32           5.38    0.0184
   Diabetes                                                                107             17.98           118          19.83   0.4154
   Hyperlipidemia                                                          148             24.87           153          25.71   0.7388
   Pregnancy                                                               14              2.35            24           4.03    0.0992
   Renal failure or dialysis                                               47              7.9             42           7.06    0.5816
   Pancreatitis                                                            19              3.19            13           2.18    0.2823
   Hematologic disease                                                     9               1.51            5            0.84    0.2822
  *Drug used*                                                                                                                    
   Bisphosphonate                                                          24              4.03            19           3.19    0.4374
   Anticoagulants                                                          103             17.31           112          18.82   0.4977
   Iloprost                                                                0               0               0            0       \-
   Statins                                                                 156             26.22           165          27.73   0.5566
   Oral Steroid + IV Steroid                                               538             90.42           540          90.76   0.8426
  *Treatment*                                                                                                                    
   Cord decompression                                                      38              6.39            48           8.07    0.2629
   Bone graft (BG)                                                         16              2.69            28           4.71    0.0653
   Osteotomy                                                               1               0.17            1            0.17    1.0000^b^
  *Duration between diagnosis date and index date (days) (mean, median)*   678 (355)       699 (383)       0.6528 ^a^           

*Abbreviations.* NONFH: nontraumatic osteonecrosis of the femoral head; TCM, traditional Chinese medicine.*∗*Chi-squared test; ^a^ t-test; ^b^Fisher\'s exact test.

The mean (median) of the follow-up period was 5.00 (4.38) years and 3.57 (3.35) years for the TCM user cohort and non-TCM user cohort, respectively.

###### 

Cox model with hazard ratios and 95% confidence intervals for total hip replacement in TCM users and covariates in NONFH patients.

  Variable                                      Total hip replacement   Crude^*∗*^   Adjusted^†^                                    
  --------------------------------------------- ----------------------- ------------ -------------- --------- ------ -------------- ---------
  *TCM use*                                                                                                                          
   No                                           151                     1.00         reference                1.00   reference       
   Yes                                          108                     0.59         (0.46--0.76)   \<.0001   0.60   (0.46--0.77)   \<.0001
  *Sex*                                                                                                                              
   Female                                       75                      1.00         reference                1.00   reference       
   Male                                         184                     0.86         (0.66--1.13)   0.2785    0.56   (0.42--0.75)   \<.0001
  *Age group*                                                                                                                        
   18--29                                       13                      1.00         reference                1.00   reference       
   30--59                                       191                     1.46         (0.83--2.56)   0.1866    1.31   (0.73--2.35)   0.3739
   ≥60                                          55                      1.01         (0.55--1.84)   0.9822    1.05   (0.55--2.02)   0.8718
  *Socioeconomic status*                                                                                                             
   Fixed premium and dependent                  144                     1.00         reference                1.00   reference       
   Insured salary grading above fixed premium   115                     1.12         (0.81--1.58)   0.4984    1.13   (0.81--1.59)   0.5226
  *Comorbidity*                                                                                                                      
   Alcohol-related disease                      229                     4.78         (3.26--6.99)   \<.0001   5.13   (3.47--7.58)   \<.0001
   Autoimmune disease                           11                      1.00         (0.54--1.82)   0.9873    1.05   (0.57--1.95)   0.876
   Diabetes                                     35                      0.7          (0.49--1.01)   0.0533    0.91   (0.61--1.35)   0.6379
   Hyperlipidemia                               63                      0.98         (0.74--1.31)   0.907     1.64   (1.17--2.30)   0.0037
   Pregnancy                                    5                       0.57         (0.24--1.39)   0.22      0.53   (0.21--1.30)   0.1631
   Renal failure or dialysis                    17                      1.01         (0.62--1.65)   0.9657    1.08   (0.65--1.81)   0.7603
   Pancreatitis                                 7                       1.15         (0.54--2.44)   0.71      0.78   (0.36--1.7)    0.5283
   Hematologic disease                          4                       1.64         (0.61--4.41)   0.3256    1.59   (0.57--4.4)    0.3750
  *Drug used*                                                                                                                        
   Bisphosphonate                               6                       0.62         (0.28--1.39)   0.2449    0.53   (0.23--1.23)   0.1399
   Anticoagulants                               30                      0.60         (0.41--0.87)   0.0078    0.65   (0.44--0.96)   0.0295
   Iloprost                                     0                                                                                    
   Statins                                      280                     0.46         (0.33--0.64)   \<.0001   0.38   (0.25--0.55)   \<.0001
   Oral Steroid + IV Steroid                    224                     0.67         (0.47--0.95)   0.0261    0.66   (0.46--0.96)   0.0281
  *Treatment*                                                                                                                        
   Cord decompression                           33                      2.09         (1.45--3.01)   \<.0001   1.74   (1.17--2.60)   0.0065
    Bone graft (BG)                             10                      0.98         (0.52--1.84)   0.9505    0.73   (0.38--1.43)   0.3597
   Osteotomy                                    0                       \-           \-             \-        \-     \-             \-

*Abbreviations.* NONFH: nontraumatic osteonecrosis of the femoral head; TCM: traditional Chinese medicine; HR: hazard ratio; CI: confidence interval.

Crude HR^*∗*^ represents relative hazard ratio; adjusted HR^†^ represents adjusted hazard ratio: mutually adjusted for TCM use, sex, age, socioeconomic status, comorbidities, drug used, and treatment in Cox proportional hazard regression.

###### 

Incidence and Cox proportional hazard regression with hazard ratios and 95% confidence intervals for total hip replacement in TCM users and non-TCM users, stratified by sex, age, and socioeconomic status.

  Variable                                      Traditional Chinese Medicine used   Crude HR   Adjusted HR^‡^                                                   
  --------------------------------------------- ----------------------------------- ---------- ---------------- ----- --------- ------- ----------------------- -----------------------
  *Total*                                       151                                 2098.05    71.97            108   2958.02   36.51   0.59(0.46--0.76)*∗∗∗*   0.60(0.46--0.77)*∗∗∗*
  *Sex*                                                                                                                                                          
   Female                                       43                                  564.26     76.21            32    719.87    44.45   0.63(0.40--1.00)*∗*     0.60(0.37--0.98)*∗*
   Male                                         108                                 1533.79    70.41            76    2238.15   33.96   0.58(0.43--0.78)*∗∗∗*   0.64(0.47--0.86)*∗∗*
  *Age group*                                                                                                                                                    
   18--29                                       10                                  136.68     73.16            3     205.69    14.59   0.21(0.06--0.77)*∗*     0.35(0.07--1.66)
   30--59                                       115                                 1420.76    80.94            76    1948.21   39.01   0.57(0.43--0.77)*∗∗∗*   0.56(0.42--0.76)*∗∗∗*
   ≥60                                          26                                  540.61     48.09            29    804.11    36.06   0.86(0.50--1.45)        1.00(0.58--1.72)
  *Socioeconomic status*                                                                                                                                         
   Fixed premium and dependent                  84                                  1220.55    68.82            60    1673.11   35.86   0.61(0.44--0.85)*∗∗*    0.58(0.41--0.81)*∗∗*
   Insured salary grading above fixed premium   67                                  973.53     74.55            48    1338.49   39.82   0.63(0.45--0.88)*∗∗*    0.53(0.34--0.83)*∗∗*

*Abbreviations.* TCM: traditional Chinese medicine; † IR: incidence rates, per 1,000 person-years; HR: hazard ratio; CI: confidence interval.

Adjusted HR^‡^ represented adjusted hazard ratio: mutually adjusted for TCM use, sex, age, socioeconomic status, comorbidities, drug used, and treatment in Cox proportional hazard regression.

*∗p*\<0.01; *∗∗ p*\<0.001; *∗∗∗ p*\<0.0001.

###### 

Ten most common formulae and single herbs prescribed for patients with NONFH in Taiwan.

  Traditional Chinese medicine                Number of person-days   Frequency   Average daily dose (g)   Average duration of prescription (days)
  ------------------------------------------- ----------------------- ----------- ------------------------ -----------------------------------------
  *Formula*                                                                                                
                                                                                                           
   Shu-Jing-Huo-Xue-Tang                      4,106                   461         8.6                      6.4
   Jia-Wei-Xiao-Yao-San                       3,926                   672         17.9                     7.1
   Long-Dan-Xie-Gan-Tang                      3,687                   504         4.1                      5.9
   Shao-Yao-Gan-Cao-Tang                      2,665                   397         4.8                      6.6
   Du-Huo-Ji-Sheng-Tang                       2,482                   187         3.2                      6.6
   Ge-Gen-Tang                                2,472                   340         18.3                     8.9
   Xue-Fu-Zhu-Yu-Tang                         2,364                   347         4.3                      6.3
   Zhi-Gan-Cao-Tang                           2,362                   260         3.7                      9.2
   Liu-Wei-Di-Huang-Wan                       2,333                   210         3.2                      7.7
   Suan-Zao-Ren-Tang                          2,297                   268         16.9                     8.2
                                                                                                           
  *Single herb*                                                                                            
                                                                                                           
   Yan Hu Suo (Rhizoma Corydalis)             4,348                   643         2.4                      6.8
   Niu Xi (Radix Achyranthis Bidentatae)      2,670                   382         1.6                      7
   Dan Shen (Radix Salviae Miltiorrhizae)     2,542                   521         1.1                      4.9
   Gan Cao (Radix Glycyrrhizae)               2,525                   324         0.8                      7.8
   Xu Duan (Dipsacus Japonicas)               2,473                   324         1.1                      7.6
   Du Zhong (Eucommia Ulmonoides)             2,371                   362         3.1                      6.5
   Hai Piao Xiao (Os Sepiae Seu Sepiellae)    2,331                   301         2.5                      7.7
   Da Huang (Radix Et Rhizoma Rhei)           2,270                   334         0.8                      6.8
   Ge Gen (Radix Puerariae)                   2,184                   322         5.1                      6.8
   Fuzi (Radix Aconiti Lateralis Preparata)   2,167                   279         2.7                      7.8

*Abbreviations.* NONFH: nontraumatic osteonecrosis of the femoral head.

[^1]: Academic Editor: Takao Namiki
